Top

Notice of Intent to Sole Source - BIONANO GENOMICS, INC

Active

NOI-CC-25-009351Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The National Institutes of Health Clinical Center has issued a notice of intent for a sole-source procurement of reagents from Bionano Genomics, Inc. under solicitation number NOI-CC-25-009351. These reagents are required for the Bionano Optical Genome Mapping assay to detect chromosomal, cytogenetic, and structural abnormalities, including large deletions, copy number abnormalities, and small structural variants in patient samples. This technology is specifically utilized for patients with cancer, cancer predisposing disorders, and complicated clinical phenotypes, and the resulting instrument capabilities will be available to other researchers in the Clinical Center for potential clinical testing validation. This acquisition is being conducted as a one-time order under the authority of FAR Subpart 13.106-1, as the purchase does not exceed the simplified acquisition threshold and Bionano is identified as the sole manufacturer and vendor capable of providing these specific reagents. The place of performance is the NIH Clinical Center in Bethesda, Maryland. Because this is a sole-source procurement, it is exempt from the competition requirements of FAR Part 6. Interested parties may submit comments or identify their capabilities to the NIH Office of Purchasing and Contracts.

General Info

Sole-source procurement of Bionano OGM assay reagents for detecting complex genetic abnormalities.

Agency

Department Of Health And Human Services → National Institutes Of Health - Cc

NAICS

334516 - Analytical Laboratory Instrument Manufacturing

Place of Performance

Bethesda, MD, 20892, USA

Set-Aside

NONE

Documents

SOW Bionano Optical Genome Mapping Reagents

sow

High

AI Contract Breakdown

Uniform Contract Format

Timeline

PostedSep 2

special-notice

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → National Institutes Of Health - Cc

Contacts1 person available

OfficeBETHESDA, MD, 20892, USA

Organization / AgencyDepartment Of Health And Human Services → National Institutes Of Health - Cc

Office AddressBETHESDA, MD, 20892, USA

Contacts

Chris Ryssa Nix

contact@example.gov

Full Description

This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. This procurement is for reagents for the Bionano Optical Genome Mapping (OGM) assay for testing samples from patient. Bionano OGM instrument and assay are used to perform optical genome mapping of patient samples to detect chromosomal, cytogenetic, and structural abnormalities that are often missed by other molecular technologies such as cytogenetics, fluorescence in situ hybridization (FISH), or next generation sequencing (NGS). Bionano is the original reagent manufacturer and sole vendor for instruments of these kinds of tests, i.e., optical genome mapping to detect large deletions and cytogenetic abnormalities, copy number abnormalities, and small structural variants from patient samples. It is advisable to use OGM for testing of samples from patients with cancer, cancer predisposing disorders, and with complicated clinical and pathological phenotypes. Furthermore, the instrument obtained from the vendor will be available to other researchers in the Clinical Center and potentially validated for clinical testing purposes. This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 - Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government. Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Ryssa Nix, Contract Specialist via email to contact@example.gov by close date.